Anyone who owns Sangamo BioSciences (SGMO), might want to take a trip over to TheStreetSweeper and check out their piece entitled "A fiery biotech with a product poised to go down in flames?"
The article questions the company's ZFN gene modification technology which is behind SB-728-T (see recent announcement of new data from Phase 2 trial).
Senior investigative reporter Sonya Colberg says "TheStreetSweeper would be astounded if SGMO produces a marketable anti-HIV product — ever."
Notably, Colberg also says "renowned HIV doctor" Joseph Sonnabend was consulted for the article and after reviewing "trial results and graphs," concluded that "no meaningful evidence was presented to indicate that [SGMO's] treatment has antiviral activity."
See also: SGMO offers shares